Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer: outcomes in the partially platinum-sensitive (platinum-free interval 6–12 months) subpopulation of OVA-301 phase III randomized trial

Andrés Poveda(Fundación Instituto Valenciano de Oncología), Ignace Vergote, Sergei Tjulandin(Russian Cancer Research Center NN Blokhin), Beihua Kong(Qilu Hospital of Shandong University), Moni Roy, Stephen Chan(University of Nottingham), Emilia Filipczyk−Cisarż, H Hagberg(Uppsala University Hospital), S.B. Kaye, Nicoletta Colombo(European Institute of Oncology), Claudia Lebedinsky(PharmaMar (Spain)), Trilok Parekh(Johnson & Johnson (United States)), J. Gómez(PharmaMar (Spain)), Y. C. Park(Johnson & Johnson (United States)), Vicente Alfaro(PharmaMar (Spain)), Bradley J. Monk(University of California, Irvine Medical Center)
Annals of Oncology
July 20, 2010
10.1093/annonc/mdq352
Cited by 168Open Access
Full Text

Abstract

Related Papers

No related papers found

Powered by citation graph analysis